These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 18636202

  • 1. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
    Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S.
    Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
    [Abstract] [Full Text] [Related]

  • 2. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST.
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [Abstract] [Full Text] [Related]

  • 3. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL.
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [Abstract] [Full Text] [Related]

  • 4. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation.
    Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J.
    Liver Transpl; 2002 Dec; 8(12):1165-74. PubMed ID: 12474157
    [Abstract] [Full Text] [Related]

  • 5. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S.
    Oncology; 2007 Dec; 72 Suppl 1():98-103. PubMed ID: 18087189
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann WH.
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [Abstract] [Full Text] [Related]

  • 7. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
    Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, Vallone P, Mastro A, Fornage BD, Curley SA.
    Ann Surg Oncol; 2005 Aug; 12(8):616-28. PubMed ID: 15965731
    [Abstract] [Full Text] [Related]

  • 8. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?
    Zavaglia C, Corso R, Rampoldi A, Vinci M, Belli LS, Vangeli M, Solcia M, Castoldi C, Prisco C, Vanzulli A, Pinzello G.
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):196-201. PubMed ID: 18301300
    [Abstract] [Full Text] [Related]

  • 9. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H.
    Cancer; 2009 Feb 01; 115(3):571-80. PubMed ID: 19117347
    [Abstract] [Full Text] [Related]

  • 10. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, El-Malah A.
    Jpn J Clin Oncol; 2007 Sep 01; 37(9):658-72. PubMed ID: 17766723
    [Abstract] [Full Text] [Related]

  • 11. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
    Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL.
    Liver Transpl; 2005 Sep 01; 11(9):1117-26. PubMed ID: 16123960
    [Abstract] [Full Text] [Related]

  • 12. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma.
    Liao GS, Yu CY, Shih ML, Chan DC, Liu YC, Yu JC, Chen TW, Hsieh CB.
    Eur J Surg Oncol; 2008 Jan 01; 34(1):61-6. PubMed ID: 17434711
    [Abstract] [Full Text] [Related]

  • 13. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis.
    Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, Conti M, Montorsi M.
    Ann Surg Oncol; 2009 Dec 01; 16(12):3289-98. PubMed ID: 19727960
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R.
    Cancer Chemother Pharmacol; 2010 Oct 01; 66(5):837-44. PubMed ID: 20041325
    [Abstract] [Full Text] [Related]

  • 15. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L.
    Eur J Cancer; 2009 Jul 01; 45(10):1788-97. PubMed ID: 19303768
    [Abstract] [Full Text] [Related]

  • 16. Combined ethanol injection therapy and radiofrequency ablation therapy in percutaneous treatment of hepatocellular carcinoma larger than 4 cm.
    Vallone P, Catalano O, Izzo F, Siani A.
    Cardiovasc Intervent Radiol; 2006 Jul 01; 29(4):544-51. PubMed ID: 16528626
    [Abstract] [Full Text] [Related]

  • 17. Radiofrequency ablation for unresectable tumors of the liver.
    Howard JH, Tzeng CW, Smith JK, Eckhoff DE, Bynon JS, Wang T, Arnoletti JP, Heslin MJ.
    Am Surg; 2008 Jul 01; 74(7):594-600; discussion 600-1. PubMed ID: 18646476
    [Abstract] [Full Text] [Related]

  • 18. [The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation].
    Chung IK, Park MJ, Kwon KT, Park YD, Chung YJ, Jeon SW, Lee MK, Seo HE, Lee YD, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH.
    Korean J Hepatol; 2005 Dec 01; 11(4):371-80. PubMed ID: 16380666
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
    Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T, Haji S.
    Dig Dis; 2007 Dec 01; 25(4):303-9. PubMed ID: 17960064
    [Abstract] [Full Text] [Related]

  • 20. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
    Hirashita T, Nakashima K, Sakai M, Sakai I.
    Gan To Kagaku Ryoho; 2007 Jul 01; 34(7):1123-6. PubMed ID: 17637554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.